Metabolic changes during 5 months treatment with olanzapine or risperidone: Preliminary results from randomized trial

被引：0
|
作者：
Smith, RC
Lindenmayer, JP
Buga, A
Matute, M
Vaidhyanathaswamy, S
Warner-Cohen, J
机构：
[1] NYU, Sch Med, Hewlett, NY USA
[2] Manhattan Psychiat Ctr, Wards Isl, NY USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2004年 / 29卷
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
引用
收藏
页码：S226 / S226
页数：1
相关论文
共 50 条
  • [1] Metabolic changes during 5 months treatment with olanzapine or risperidone: Preliminary results from randomized trial
    Smith, RC
    Lindenmayer, JP
    Buga, A
    Matute, M
    Vaidhyanathaswamy, S
    Butler, E
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 570 - 570
  • [2] Obsessive-compulsive symptoms during treatment with olanzapine or risperidone. Preliminary results from a prospective study
    de Haan, L
    Beuk, N
    Linszen, DH
    Dingemans, P
    SCHIZOPHRENIA RESEARCH, 2000, 41 (01) : 191 - 191
  • [3] Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: Results from a US randomized controlled trial
    Namjoshi, M
    Young, C
    Huang, L
    Edgell, ET
    Breier, A
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S315 - S315
  • [4] Cost-effectiveness of olanzapine compared to risperidone and haloperidol in the treatment of patients with schizophrenia: Results from a US randomized controlled trial
    Namjoshi, M
    Young, CA
    Huang, L
    Edgell, E
    Breier, A
    SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 296 - 296
  • [5] Metabolic and inflammatory parameters changes in schizophrenic patients during three months of treatment with long acting risperidone
    Karlovic, D.
    Solter, V.
    Potkonjak, J.
    EUROPEAN PSYCHIATRY, 2007, 22 : S157 - S157
  • [6] Body composition and metabolic changes during antipsychotic treatment. A randomized trial comparing sertindole and olanzapine - study design presentation
    Linne, Y.
    Roessner, S.
    Neovius, M.
    NORDIC JOURNAL OF PSYCHIATRY, 2007, 61 (06) : 499 - 499
  • [7] Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol
    Purdon, SE
    Jones, BDW
    Stip, E
    Labelle, A
    Addington, D
    David, SR
    Breier, A
    Tollefson, GD
    ARCHIVES OF GENERAL PSYCHIATRY, 2000, 57 (03) : 249 - 258
  • [8] Changes of metabolic parameters during electroconvulsive treatment of schizophrenia: Preliminary results
    Wysokinski, Adam
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2015, 69 (05) : 305 - 305
  • [9] A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP)
    Stroup, T. Scott
    McEvoy, Joseph P.
    Ring, Kimberly D.
    Hamer, Robert H.
    LaVange, Lisa M.
    Swartz, Marvin S.
    Rosenheck, Robert A.
    Perkins, Diana O.
    Nussbaum, Abraham M.
    Lieberman, Jeffrey A.
    AMERICAN JOURNAL OF PSYCHIATRY, 2011, 168 (09) : 947 - 956
  • [10] Costs of olanzapine treatment compared with haloperidol for schizophrenia: Results from a randomized clinical trial
    Hamilton, SH
    Revicki, DA
    Genduso, LA
    Tollefson, GD
    SCHIZOPHRENIA RESEARCH, 1998, 29 (1-2) : 149 - 149
12345